Standard therapy for metastatic small cell carcinoma of the prostate (SCCP) remains undefined. We have effectively treated relapsed SCCP with amrubicin. A 72-year-old patient, diagnosed with T4N1M0 prostate cancer, started hormonal therapy in May 2012, elsewhere, and his prostate-specific antigen levels remained low.
We herein present the results of the first Italian Association of Radiotherapy and Clinical Oncology (AIRO) survey regarding salvage external beam re-irradiation of local prostate cancer relapse named PROLAPSE.
Immunosenescence might impact immunotherapy (IT) in patients with advanced age. However, pivotal studies were not powered for this clinical question. Our aim is to explore toxicity (primary objective) and activity (secondary objective) of immune checkpoint inhibitors (ICIs) in patients with renal cell (RCC) and urothelial carcinoma (UC) older than 75 years compared to the younger population.
Little is known about the association of diet with risk of bladder cancer. This might be due to the fact that the majority of studies have focused on single food items, rather than dietary patterns, which may better capture any influence of diet on bladder cancer risk.
A 38-year-old female developing pelvic lymph node recurrence (cN2) of bladder cancer was referred to our hospital. Eighteen months earlier, she had received complete transurethral resection of bladder tumor and pathological diagnosis of muscle-invasive urothelial carcinoma with micropapillary variant had been made.
Alicia Morgans: Hi, this is Alicia Morgans, GU medical oncologist and Associate Professor of Medicine at Northwestern University in Chicago in the United States. I am so excited to have here with me today, Dr. Tom Powles, who’s a Professor of GU Oncology, as well as the Director of the Barts Cancer Centre in London, […]
Lecture Presentation: Phillip Koo: Hi, this is Phillip Koo from Banner MD Anderson Cancer Center in Phoenix, Arizona. Very fortunate to have with us today Dr. Michael Hofman, who’s the Director of the Prostate Theranostics and Imaging Centre of Excellence at the Peter MacCallum Cancer Center. And he’s going to be speaking to us today, […]
Prostate cancer is a clinically heterogeneous disease with many patients having an indolent course requiring no interventions and others who either present with or progress to metastasis. While underlying dominant driving mutations are not widespread, there have been a number of key genomic mutations that have been consistently identified in prostate cancer patients, across the […]
Nivolumab is an FDA-approved immune checkpoint for treating platinum-resistant metastatic or surgically unresectable urothelial carcinoma (mUC). The development of predictive biomarkers to predict response to immune checkpoint inhibitors have been challenging.
Ashish Kamat: Welcome to UroToday’s Bladder Cancer Center of Excellence. I’m Ashish Kamat from MD Anderson Cancer Center in Houston. And it’s my great pleasure to be joined today by Anne Schuckman who’s at the USC Institute of Urology and has done a lot of work with blue light cystoscopy with Cysview®, and she had […]
